Opendata, web and dolomites

DECODE SIGNED

reDucing the health and Economic COst of Diagnostic uncErtainty: launch and randomized control trial of the first validated bacterial versus viral test

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DECODE project word cloud

Explore the words cloud of the DECODE project. It provides you a very rough idea of what is the project "DECODE" about.

thousands    multicentre    children    data    hospitalization    diagnostic    share    patient    diagnostics    constraints    regulatory    tool    healthcare    initiate    expand    indistinguishable    primary    inappropriate    bacterial    distinguishing    misuse    clinicians    poc    release    world    care    validated    decodes    blind    blood    suspected    validation    memed    infection    suitable    workflow    compatible    market    capillary    commercially    actionable    externally    complete    leads    patients    reduces    instances    bv    conduct    gaps    fight    broad    routine    cleared    dach    superiority    problem    key    500    pioneering    clinician    risk    trade    immune    biomarkers    double    body    reducing    minutes    avoidable    clinically    concurrently    gap    trial    gather    global    platform    solution    15    antimicrobial    threats    infections    routinely    clinical    inferior    outcomes    rct    serum    enrolling    utility    economic    decide    confidence    applicability    elevated    resistance    demonstrated    settings    viral    runs    acute    health    randomized    amr    burden    efforts    decode    samples   

Project "DECODE" data sheet

The following table provides information about the project.

Coordinator
MEMED DIAGNOSTICS LTD 

Organization address
address: NAHUM HETH STREET 5
city: TIRAT CARMEL
postcode: 39120
website: www.me-med.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙571˙427 €
 EC max contribution 2˙499˙999 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEMED DIAGNOSTICS LTD IL (TIRAT CARMEL) coordinator 2˙499˙999.00

Map

 Project objective

Problem: Clinicians routinely face diagnostic uncertainty because acute infections are often clinically indistinguishable and today’s diagnostics have constraints. This uncertainty leads to inappropriate patient management, including antimicrobial misuse and avoidable hospitalization. The associated health economic burden are inferior patient outcomes, elevated costs, and antimicrobial resistance (AMR), one of the top 10 threats to global health. Potential solution: In many instances, the clinician only needs to know with confidence if the infection is bacterial or viral to decide how to manage a patient suspected to have an acute infection. We have developed and validated MeMed BV™ - a pioneering test for distinguishing between bacterial and viral infections that decodes the body’s immune response to infection. BV™ has been both double-blind and externally validated in clinical studies enrolling thousands of patients and demonstrated superiority to biomarkers in routine use. Concurrently, we have developed Key™, an easy-to-use POC platform that runs BV™ in 15 minutes. Gap: Broad impact of BV™ and market share require high-risk efforts to address the following major gaps: 1. Real world evidence of usage and impact on workflow. 2. Validation of clinical utility in a randomized control trial (RCT). 3. Expand applicability to primary care settings. Proposed objectives: 1. To initiate market release in DACH and gather real world data. 2. To conduct a multicentre RCT enrolling 500 children. 3. Complete development of BV™ compatible with capillary blood. Impact: DECODE will take BV™ on Key™ from a test regulatory cleared for use to one that is available commercially and adopted in routine care, has validated clinical utility and is suitable for both serum and capillary blood samples. By providing an actionable tool that reduces diagnostic uncertainty, this project will improve patient outcomes while reducing healthcare costs and help fight AMR.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DECODE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DECODE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More